You are here

Article Text

Article menu

Download PDFPDF

PostScript
Letter
Efficacy of mesalazine in IBS
Free
  1. Thazin Min1,
  2. Alexander C Ford1,2
  1. 1 Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK
  2. 2 Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, UK
  1. Correspondence to Dr Alexander Ford, Leeds Gastroenterology Institute, Room 125, 4th Floor, Bexley Wing, St. James's University Hospital, Beckett Street, Leeds LS9 7TF, UK; alexf12399{at}yahoo.com

https://doi.org/10.1136/gutjnl-2015-309593

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Editor,

    We read the papers by Barbara et al 1 and Lam et al 2 with interest. The authors reported the results of two randomised controlled trials (RCTs) of mesalazine in IBS. These are the largest studies examining the efficacy of this drug in IBS, to date, and the authors are to be applauded for conducting them.

    The efficacy of mesalazine in UC is undisputed.3–5 However, the observation that a subset of patients with IBS, particularly those with a post-infective aetiology, may demonstrate low-grade colonic mucosal inflammatory changes has led to a renewed interest in the use of the drug for this condition.6 …

    View Full Text